MachFBaigentCCatapanoAL, et al.
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J2020;
41: 111–188.
2.
GaudetDWattsGFRobinsonJG, et al.
Effect of alirocumab on lipoprotein(a) over ≥1.5 years (from the phase 3 ODYSSEY program). Am J Cardiol2017;
119: 40–46.
3.
BittnerVASzarekMAylwardPE, et al.;
ODYSSEY OUTCOMES Committees and Investigators. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol2020;
75: 133–144.
4.
SchwartzGGStegPGSzarekM, et al.; ODYSSEY OUTCOMES Committees and Investigators. Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: Role of lipoprotein(a) and modification by alirocumab: Prespecified analysis of a randomized clinical trial. Circulation. Epub ahead of print 29 March 2020. DOI: 10.1161/CIRCULATIONAHA.120.046524.
5.
Reyes-SofferGPavlyhaMNgaiC, et al.
Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation2017;
135: 352–362.
6.
TsimikasSGordtsPLSMNoraC, et al.
Statins and increases in Lp(a): An inconvenient truth that needs attention. Eur Heart J2020;
41: 192–193.
7.
McCormickSPASchneiderWJ.Lipoprotein(a) catabolism: A case of multiple receptors. Pathology2019;
51: 155–164.
8.
WattsGFChanDCSomaratneR, et al.
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J2018;
39: 2577–2585.
9.
EnkhmaaBAnuuradEZhangW, et al.
The roles of 1 apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab. J Lipid Res2017;
58: 2008–2016.
10.
TavoriHChristianDMinnierJ, et al.
PCSK9 association with lipoprotein(a). Circ Res2016;
119: 29–35.
11.
VillardEFThedrezABlankensteinJ, et al.
PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: An effect blunted by alirocumab. JACC Transl Sci2016;
1: 419–427.
12.
EdmistonJBBrooksNTavoriH, et al.
Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9. J Clin Lipidol2017;
11: 667–673.
13.
ShapiroMDMinnierJTavoriH, et al.
Relationship between low-density lipoprotein cholesterol and lipoprotein(a) lowering in response to PCSK9 inhibition with evolocumab. J Am Heart Assoc2019;
8: e010932.
14.
MahmoodTMinnierJItoMK, et al. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY phase 3 studies. Eur J Prev Cardiol. Epub ahead of print 10 April 2020. DOI: 10.1177/2047487320915803.
15.
MacchiCBanachMCorsiniA, et al.
Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents. Eur J Prev Cardiol2019;
26: 930–949.
16.
RuscicaMWattsGFSirtoriCR.PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): Making choices in an era of RNA-based therapies. Eur J Prev Cardiol2019;
26: 998–1000.
